Pages that link to "Q37167300"

The following pages link to Combined modality immunotherapy and chemotherapy: a new perspective (Q37167300):

Displaying 27 items.

• Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment (Q27335748) (← links)
• Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy (Q28485036) (← links)
• Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy (Q30402590) (← links)
• Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice (Q30493889) (← links)
• CD8 tumor-infiltrating T cells are trapped in the tumor-dendritic cell network. (Q30533257) (← links)
• What's the place of immunotherapy in malignant mesothelioma treatments? (Q33781142) (← links)
• Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis (Q34170003) (← links)
• Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated Mechanisms (Q34343736) (← links)
• Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination (Q34759603) (← links)
• Immunological and Clinical Effects of Vaccines Targeting p53‐Overexpressing Malignancies (Q34898280) (← links)
• INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect (Q35136043) (← links)
• A cell-based high-throughput screen to identify synergistic TRAIL sensitizers (Q35200982) (← links)
• Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy (Q36114222) (← links)
• The immunologic aspects of poxvirus oncolytic therapy (Q36115128) (← links)
• Immunity, ageing and cancer (Q36930979) (← links)
• Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy (Q37035522) (← links)
• A new era in anticancer peptide vaccines (Q37699160) (← links)
• Therapeutic cancer vaccines in combination with conventional therapy (Q37771267) (← links)
• Trovax ® Vaccine Therapy for Renal Cell Carcinoma (Q37965748) (← links)
• Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. (Q38047057) (← links)
• Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. (Q38366904) (← links)
• Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect (Q39409268) (← links)
• Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies (Q39610803) (← links)
• Cancer immunotherapy. (Q39958332) (← links)
• The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix (Q40391633) (← links)
• Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice (Q47361686) (← links)
• Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme (Q48467671) (← links)